148 related articles for article (PubMed ID: 25460502)
1. Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.
Sun NK; Huang SL; Chang PY; Lu HP; Chao CC
Oncotarget; 2014 Dec; 5(23):11939-56. PubMed ID: 25460502
[TBL] [Abstract][Full Text] [Related]
2. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
[TBL] [Abstract][Full Text] [Related]
4. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
[TBL] [Abstract][Full Text] [Related]
5. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
6. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
[TBL] [Abstract][Full Text] [Related]
7. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
8. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
9. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
11. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
13. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance.
Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG
Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
Tang J; Cao L; Yi H; Tang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
[TBL] [Abstract][Full Text] [Related]
19. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.
Li Y; Tang K; Zhang H; Zhang Y; Zhou W; Chen X
Mol Med Rep; 2011; 4(4):739-46. PubMed ID: 21584498
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
